Gary Kirsh, MD

home / authors / gary-kirsh-md

Articles

Dr. Kirsh on Advancements in Diagnosing Prostate Cancer

Dr. Kirsh on Advancements in Diagnosing Prostate Cancer

Gary Kirsh, MD
May 5th 2017

Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses advancements in diagnosing patients with prostate cancer.

Read More

Dr. Gary Kirsh on This Exciting Phase in Prostate Cancer Care

Dr. Gary Kirsh on This Exciting Phase in Prostate Cancer Care

Gary Kirsh, MD
November 4th 2016

Gary Kirsh, MD, President of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses this exciting phase in prostate cancer care. Kirsh shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.

Read More

Dr. Kirsh Discusses the Future of Treating Prostate Cancer

Dr. Kirsh Discusses the Future of Treating Prostate Cancer

Gary Kirsh, MD
November 10th 2015

Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses the future of treatment for prostate cancer.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data